

Vaccine Highlights

Recommendations, schedules, and more

Editor's note: The information in Vaccine Highlights is current as of February 15, 2013.

The next ACIP meetings

A committee of 15 national experts, the Advisory Committee on Immunization Practices (ACIP) advises CDC on the appropriate use of vaccines. ACIP meets three times a year in Atlanta; meetings are open to the public. Upcoming meetings will be held on Feb. 20–21 and June 19–20. For more information, visit www.cdc.gov/vaccines/recs/acip.

ACIP periodically issues public health recommendations on the use of vaccines. Clinicians who vaccinate should have a current set for reference. Published in the *Morbidity and Mortality Weekly Report (MMWR)*, ACIP recommendations are easily available. Here are sources:

- Download them from links on IAC's website: www.immunize.org/acip.
- Download them from CDC's website: www.cdc.gov/vaccines/pubs/acip-list.htm.

New and updated ACIP recs

Child and adult immunization schedules.

On Jan. 28, CDC published "Recommended Immunization Schedules for Persons Aged 0 Through 18 years and Adults Aged 19 Years and Older—United States, 2013." The child and teen schedule is issued jointly by ACIP, AAP, and AAFP. The adult schedule is issued jointly by ACIP, AAFP, ACOG, ACP, and ACNM. For the child schedule, go to www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html. For the adult schedule, go to www.cdc.gov/vaccines/schedules/hcp/adult.html.

Tdap in pregnancy. On Dec. 6, CDC posted "ACIP Provisional Updated Recommendations on Use of Tdap Vaccine for Pregnant Women" on its website. The recommendations advise prenatal care providers to administer a dose of Tdap during each pregnancy irrespective of the patient's prior history of receiving Tdap. It is anticipated that CDC will release the final updated recommendations in the Feb. 22 issue of *MMWR*. To access the new recommendations, visit www.cdc.gov/vaccines/pubs/ACIP-list.htm.

MMR. On Dec. 6, CDC posted "ACIP Provisional Recommendations: Prevention of Measles, Rubella, Congenital Rubella Syndrome (CRS), and Mumps" on its website. The provisional recommendations have new information regarding (1) the definition of evidence of immunity to measles, rubella, and mumps, (2) the use of immune globulin for measles post-exposure prophylaxis, and (3) the use of MMR vaccine in people who are HIV-infected. Access provisional recommendations at www.cdc.gov/vaccines/recs/provisional/default.htm.

Meningococcal. On Jan. 25, CDC published "Infant Meningococcal Vaccination: ACIP Recommendations and Rationale." ACIP recommends that high-risk infants receive a 4-dose series of Hib-MenCY vaccine (MenHibrix; GlaxoSmithKline) starting at age 2 months. To obtain the recommendations, go to www.cdc.gov/mmwr/pdf/wk/mm6203.pdf (pages 52–54).

Influenza vaccine news

On Jan. 16, FDA issued a press release announcing it had approved the use of the first influenza vaccine produced using a novel manufacturing technology (Flublok, Protein Sciences Corp). To read the press release, go to: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm?source=govdelivery.

On Dec. 14, FDA approved a request by GlaxoSmithKline to supplement its biologics license application for Fluarix influenza virus vaccine to include a quadrivalent formulation for use in people age 3 years and older. To access the package insert, go to www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220624.pdf.

On Nov. 20, FDA issued a press release announcing that it had approved the use of the first influenza vaccine produced using cultured animal cells (Flucelvax; Novartis Vaccines and Diagnostics GmbH). For the press release, go to www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm.

PCV13 vaccine news


On Jan. 25, FDA approved the expanded age indication for use of Prevnar 13 (Pfizer Inc.) in children and teens age 6 through 17 years for prevention of invasive pneumococcal disease caused by serotypes in the vaccine. For the package insert go to www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201669.pdf.

VIS and CDC news

On Nov. 16, CDC posted an updated and redesigned pediatric multi-vaccine VIS. To access the VIS and 7 translations, go to www.immunize.org/vis/vis_multi_vaccine_infants.asp.

On Nov. 27, CDC posted its highly informative *Vaccine Storage & Handling Toolkit* on its website. It includes information on the following: (1) points to consider in selecting, maintaining, and using vaccine storage units and thermometers; (2)

Subscribe to **IAC Express!**
www.immunize.org/subscribe



Get weekly updates on vaccine information while it's still news!

All the news we publish in "Vaccine Highlights" will be sent by email to you every Tuesday. Free! To sign up for IAC Express—and any of our other free publications—visit

www.immunize.org/subscribe

consistent maintenance of the cold chain; (3) routine storage and handling practices; (4) inventory management; and (5) emergency procedures for protecting vaccine inventories. The toolkit web page offers related resources such as training materials, slide sets, and other useful items. To access the toolkit web page, go to www.cdc.gov/vaccines/recs/storage/toolkit.

New and updated VISs

The use of most Vaccine Information Statements (VISs) is mandated by federal law. Listed below are the dates of the most current VISs. Check your stock of VISs against this list. If you have outdated VISs, print current ones from IAC's website at www.immunize.org/vis. You'll find VISs in more than 30 languages.

DTaP/DT/DTP	5/17/07	MMRV	5/21/10
Hepatitis A	10/25/11	PCV13	4/16/10
Hepatitis B	2/2/12	PPSV	10/6/09
Hib	12/16/98	Polio	11/8/11
HPV (Cervarix)	5/3/11	Rabies	10/6/09
HPV (Gardasil)	2/22/12	Rotavirus	12/6/10
Influenza (LAIV)	7/2/12	Shingles	10/6/09
Influenza (TIV)	7/2/12	Td/Tdap	1/24/12
Japan. enceph.	12/7/11	Typhoid	5/29/12
Meningococcal	10/14/11	Varicella	3/13/08
MMR	4/20/12	Yellow fever	3/30/11

Multi-vaccine VIS11/16/12
(for 6 vaccines given to infants/children:
DTaP, IPV, Hib, HepB, PCV, RV)

For a ready-to-print version of this table for posting in your practice, go to www.immunize.org/catg.d/p2029.pdf.